Top Markets
Coin of the day
Scandion Oncology A/S Scandion Oncology A/S

Scandion Oncology A/S

SCOL
Clasificación en acciones #40631
Operating as a clinical-stage biotechnology company, Scandion Oncology A/S... Operating as a clinical-stage biotechnology company, Scandion Oncology A/S specializes in creating pharmaceutical solutions to combat resistance to chemotherapy. Their primary investigational drug, SCO-101, an orally administered compound, is currently progressing through Phase Ib and Phase II clinical studies with cancer patients. Another pipeline candidate, SCO-201, is undergoing preclinical assessment for its potential efficacy against solid tumors. Established in 2017, Scandion Oncology A/S maintains its headquarters in Copenhagen, Denmark.
Precio por acción
$0.00045794
Última sincronización: 2025-07-11
Capitalización bursátil
$107.51K
Cambio (1 día)
-36.01%
Cambio (1 año)
0.00%
País
DK
Comercio Scandion Oncology A/S (SCOL)

Categoría

Ratio P/B de Scandion Oncology A/S (SCOL)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Scandion Oncology A/S, el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Scandion Oncology A/S desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE